Article history: Received 9 September 2016 Accepted 12 October 2016 Background: Mild to moderate depressive symptoms are common during treatment for non-metastatic breast cancer. The goal of this secondary analysis was to determine if depressive symptoms predict clinical outcomes at long-term follow-up. Methods: From 1998 to 2005, we interviewed 231 women with the Hamilton Rating Scale for Depression who were participating in a psychosocial study 2-10 weeks post-surgery for non-metastatic breast cancer (Stage 0-IIIb). We conducted Kaplan Meier (K-M) curves and Cox proportional hazards (PH) models to examine associations between depressive symptoms, overall survival, and disease-free survival at 8-15-year follow-up. Results: A total of 95 women (41.1%) scored in the mild-moderately depressed range. Non-depressed women had longer overall survival (M = 13.56 years; SE = 0.26) than those in the mild/moderate depressed group (M = 11.45 years; SE = 0.40), Log-rank χ 2 (1) = 4.41, p = 0.036. Cox PH models, adjusting for covariates, showed comparable results: mild/moderate depressive symptoms hazard ratio = 2.56, [95% CI, 1.11 to 5.91], p = 0.027. Similar results were observed in a subsample with invasive disease (n = 191). Depression category did not predict disease-free survival in the overall or invasive sample. Conclusions: Screening and referrals for treatment of depressive symptoms, even at subclinical levels, is important early in treatment. A randomized trial is warranted to determine effects of depressive symptoms on clinical outcomes.
Introduction
For women, breast cancer is the most common cancer and the second highest cause of cancer death. Survival rates for non-metastatic disease are 78% over 15 years [1] . Psychosocial factors such as depression influence mortality in cancer patients [2] [3] [4] [5] [6] [7] . Estimates of prevalence of depression in women with breast cancer range as high as 37% [8] . Some individual studies [9] [10] [11] [12] and meta-analyses [4, 6, 7] conclude that depressive symptoms predict higher all-cause mortality, though not breast cancer recurrence [6] . Other studies show no relationship between depressive symptoms and survival among breast cancer patients [13, 14] .
Discrepancies among results may be attributable to inclusion of patients at different disease stages and points in treatment. Inconsistencies may reflect differences in how depression was operationalized and where in the depression continuum cohorts were distributed. Many women treated for breast cancer report depressive symptoms that are serious but below the threshold for a diagnosis of Major Depressive Disorder (MDD) [15] . It is valuable to know whether differences across the subclinical depressive symptom continuum influence health outcomes.
We examined early stage (0-IIIb) breast cancer patients who were free of major psychopathology, including major depressive disorder. We tested whether the magnitude of depressive symptoms reported post-surgery predicted overall survival or disease-free survival at 8-15-year follow-up (11-year median) . Given the low risk of mortality and recurrence for women with non-invasive (stage 0) breast cancer, we also tested whether depressive symptoms were associated with disease endpoints in a restricted subsample of women with invasive cancer.
Materials and methods

Study design and patients
Participants were women 2-10 weeks post-surgery for stage 0-IIIb breast cancer and enrolled in a randomized controlled trial of stress management between 1998 and 2005. This single center, single blind, randomized, parallel assignment efficacy trial was approved by the University of Miami (UM) Institutional Review Board (ClinicalTrials.gov NCT01422551) as described elsewhere [2] . Briefly, women were recruited via advertising and physician referrals from private practices and the UM Sylvester Cancer Center in South Florida. A total of 106 women were excluded because they were not between the ages of 21-75 years old, were not fluent in English, had stage IV breast cancer or prior cancer (except minor skin cancers), had begun adjuvant treatment, had other major medical conditions, current psychosis, active suicidality, MDD, or panic disorder, or were previously psychiatrically hospitalized.
Procedures
A total of 240 women who met entry criteria signed informed consent, completed baseline psychosocial assessments, and were randomized to either Cognitive-Behavioral Stress Management (CBSM) intervention or a 1-day psychoeducational seminar control group. At the baseline assessment, prior to randomization, 231 participants completed the Hamilton Depression Rating Scale (HDRS) [16] , administered by a Masters-level psychologist blinded to study condition. In 2013, 8-15 years post-study enrollment (11-year median), women were recontacted for participation in a follow-up study for which they selfreported their disease status. Participants' medical charts were reviewed to confirm breast cancer recurrence or disease-free status. To obtain vital statistics regarding death, cause, and date of death, a linkage study was conducted with the Florida Cancer Data System (FCDS) and approved by the Florida Department of Epidemiology and Institutional Review Board of the Florida Department of Health. We supplemented data from the state registry with national online databases. The current study used data from the baseline HDRS assessment and 11-year survival and recurrence data. Demographic, medical, and treatment-related information was gathered by self-report at baseline and verified with medical chart reviews.
Depressive symptoms
The interviewer-based 17-item HDRS [16] was administered with a Structured Interview Guide to assess depressive symptom severity over the previous week. Participants rated items on a Likert-type scale with eight items on a 0 (absent) to 4 (severe) scale and nine items on a 0 to 2 scale. Items include presence of depressed mood, anhedonia, psychomotor slowing or agitation, appetite change, and sleep difficulties. Items are summed for a total score (range 0-50). We examined total depressive symptom severity both on a continuous scale and using a clinical cutoff [17] to classify women into a mild/moderate depressive symptom group (HDRS scoreN7) vs. a low depressive symptom group (HDRS score ≤ 7). A final categorization [18] sub-divided women in the former group into those with mild (HDRS = 8-16) versus moderate (HDRS = 17-23) levels. Test reliability was adequate (α = 0.78).
Statistical analysis
The Statistical Package for the Social Sciences (SPSS; version 21.0) was used to conduct time-to-event analyses and investigate differences in baseline HDRS depressive symptoms and time to two clinical disease endpoints at 8-15-year follow-up: all-cause mortality and breast cancer recurrence. Overall survival time and disease-free interval were calculated as the time from randomization (2-10 weeks post-surgery) to event. Data were screened for outliers and non-normality. The Proportionality Hazards Assumption was met for all regressions. Data were censored for women who did not have a death or recurrence at the time of follow-up, were lost to follow-up, or had previously dropped out of the study. Data were right censored and met the assumption of non-informative censoring [19] .
Chi-square tests and one-way ANOVAs determined any baseline differences in demographic, medical, and treatment-related variables between mild/moderate versus low depressive subgroups. Kaplan-Meier (K-M) survival curves 2 were plotted to determine whether women classified with mild/moderate versus low depressive symptoms differed on clinical disease endpoints at 8-15 years. Significance of log-rank tests were interpreted at a two-sided alpha of 0.05. Next, covariates known to theoretically influence the outcomes were included and multivariate comparisons were conducted with adjusted Cox proportional hazards (PH) models [20] to examine the effects of depressive symptoms on clinical disease outcomes beyond effects of potential confounders. Covariates -age [1] , race/ ethnicity [21] , partner status [22] , chemotherapy [23] , and study condition (control vs. intervention) -were manually entered into the regression model [24] . Significance of hazard ratios (HR) estimates was based on a twosided alpha of 0.05, and confidence intervals (at 95%) were obtained for each estimate. Unadjusted KM survival curves and adjusted Cox PH models tested for differences in outcomes by the 3-group categorization of depressive symptoms (none/low, mild, moderate). Cox PH models were repeated using a continuous depressive symptom severity score as a predictor in both unadjusted and adjusted models. Finally, all analyses were repeated in the subgroup of women diagnosed with stage IIIIb (i.e., invasive subsample), thereby excluding women with stage 0 (lobular or ductal carcinoma in-situ) breast cancer.
Results
Participant characteristics
Among 240 participants enrolled, 231 completed the HDRS and 9 declined the interview. At enrollment, women were just over one month from surgery (M = 40.74 days, SD = 23.20). Women were an average of 50.16 (SD = 8.97) years old, with 37.7% of an ethnic minority group. The average HDRS score was 7.52 (SD = 5.46) with 136 (58.9%) scoring ≤ 7 (low depressive symptom group) and 95 (41.1%) N7 (moderate/mild depressive symptom group). Depression severity ranges according to the Zimmerman et al. [17] classification were as follows: none (0-7) = 136 (58.9%); mild (8-16) = 75 (32.5%); moderate (17-23) = 20 (8.7%); severe (≥24) = 0 (0%).
At the 8-15-year follow-up, 28 (12.1%) of the 231 had passed away. Cause of death for 21 was specified as breast cancer-related. A total of 44 (19.0%) had experienced a breast cancer recurrence and were alive at follow-up. Participants who were alive or had not experienced a recurrence were censored in the relevant analyses. Low and moderate/mild depressive subgroups significantly differed at baseline on age (p = 0.014), race/ethnicity (p = 0.013), and partner status (p = 0.046).
There was a slight difference in receipt of chemotherapy 3 between groups that did not reach statistical significance (p = 0.080). These factors were included as covariates in adjusted Cox PH models to control for potential confounding. Low and high depressive symptom subgroups did not differ with regard to demographic, medical (e.g., stage) or other treatment-related (e.g., extent of surgery, radiation, hormonal therapy) characteristics (Table 1) . When examining severity of depressive symptoms on a continuous scale, the unadjusted Cox PH model showed greater HDRS scores associated with shorter survival (HR, 1.08, 95% CI, 1.01 to 1.14; p = 0.015). Adjusting for covariates yielded similar results; greater depressive symptoms were associated with shorter survival (HR, 1.08, 95% CI, 1.02 to 1.16; p = 0.016; Table 2 ).
Disease-free interval
No significant differences were found in disease-free interval for moderate/mild versus low HDRS depressive symptoms, continuous depressive symptoms, or the 3-group categorization of depressive symptoms in KM survival curves or adjusted Cox PH models (Table 2) . Fig. 2 ). Adjusted Cox PH models in this subsample also showed that the low depressive group had longer survival than the moderate/mild group, (High depressive mortality HR 2.59, 95% CI, 1.12 to 5.97; p = 0.026, Supplemental Table 3 ).
Depressive symptom severity as three groups was also associated with survival in this subsample (Log-rank χ 2 (2) = 8.81, p = 0.012). Considering severity of depressive symptoms on a continuum, unadjusted Cox PH model showed greater HDRS scores were associated with shorter survival (HR, 1.08, 95% CI, 1.01 to 1.14; p = 0.015). Adjusting for covariates yielded similar results, with greater depressive symptoms associated with shorter survival (HR, 1.08, 95% CI, 1.01 to 1.16; p = 0.018, Supplemental Table 3 ).
No significant differences were found in disease-free interval for moderate/mild versus low HDRS depressive symptoms, continuous depressive symptoms, or the 3-group categorization of depressive symptoms in KM survival curves or adjusted Cox PH models invasive tumor subsample (Supplemental Table 3 ).
Discussion
This study found greater postsurgical depressive symptoms in 231 patients with non-metastatic breast cancer were associated with shorter survival (all-cause) at 8-15-year follow-up. Women who report low depressive symptoms before they begin adjuvant treatment have a survival advantage beyond treatment and demographic factors that differed between them and more depressive women. Findings were robust whether depressive symptoms were tested on a severity continuum, as low versus mild/moderate depressive symptoms subgroups, or as no/ low versus mild versus moderate depressive symptom subgroups using accepted clinical cut-offs [17, 18] . Depressive symptoms were not associated with breast cancer recurrence. Similar results were obtained when examining women with invasive tumors only (stage I-IIIb).
Results are consistent with studies showing that depressive symptoms predict mortality in breast cancer, as demonstrated in samples of non-metastatic [10, 11] and metastatic breast cancer [9] , and in a study combining all breast cancer stages [12] . Findings are in line with meta-analyses showing that higher levels of depressive symptoms predict elevated mortality in cancer patients [6, 7] and in breast cancer patients specifically [4] . As did previous research [6, 13] , the current study failed to find an association between depressive symptoms and breast cancer recurrence. It is possible that other behavioral and psychosocial factors not measured in this study (e.g., accessibility to or compliance with follow-up care, patient-physician communications) could influence detection of disease recurrence [25] .
The average follow-up for studies that show depressive symptoms to predict mortality is 5 years [6] . This study extends these findings by showing a similar association in a longer follow-up of 8-15 years (11-year median). This study is novel in that we observed these associations in women who did not initially have MDD or major psychopathology. This suggests that the findings are generalizable to the majority of women who experience non-psychiatric levels of distress during primary treatment. Over 37% of the sample was of a racial/ethnic minority thereby increasing generalizability of the findings beyond nonHispanic White women.
Proposed mechanisms by which depressive symptoms predict poorer survival in breast cancer include physiological (i.e., immune and neuroendocrine function) [2, 14, 26] and behavioral pathways (i.e., treatment non-adherence, maladaptive coping) [25, 27, 28] . Cortisol dysregulation, frequently observed in depressed patients [29] , predicts shorter overall survival in breast cancer [26] , and is a potential mediating pathway [14] , In breast cancer patients, inflammatory cytokines are associated with degree of depressive symptoms [30] , and evidence 3 The influence of depression on mortality is shown to be independent of disease stage. suggests that elevated inflammation may promote pathophysiologic processes [3] . Alleviating depressive symptoms during primary treatment may help normalize neuroendocrine and inflammatory processes [31] , which could provide health benefits.
Breast cancer patients with depressive symptoms may be less likely to adhere to treatments, medical follow-ups, screening, and recommendations for health maintenance [25, 32] , that may influence survival outcomes. Depressed patients often suffer from a lack of social support [27] , have more difficulty handling complex healthcare regimens [7] , and may employ maladaptive coping strategies [28] , all of which may increase risk for mortality. Given that lower socioeconomic status is a risk factor for depression, it is possible that more depressed patients in our sample had less access to healthcare or resources, though we controlled for education and employment status. Future research should aim to assess mediators of the relationship between depressive symptoms and mortality observed here and elsewhere [7] .
Importantly, depressive symptoms in the current study were reported in the days following diagnosis and treatment initiation, which are shown to be stress-inducing [33] and lead to increased risk for a depressive episode. Psychiatric symptoms increase risk for disease-related morbidity and mortality [34] ; however, the psychological needs of these patients are largely unmet. Given the amount of patientprovider interaction around the time of diagnosis and treatment initiation, healthcare providers could capitalize on this window of opportunity to provide skills to buffer the effects of stress and downstream potential for a depressive episode. A limitation of the study is that all participants were included regardless of distress level and depression levels were truncated, in fact, by the exclusion of those diagnosed with MDD. Hence the sample may be representative of newly diagnosed patients with a range of nonsevere depressive symptoms, but may not be generalizable to those with clinical levels of depressive symptoms. However, the exclusion of patients with current MDD or prior psychiatric hospitalizations, and the low prevalence of patients taking antidepressants at study entry, suggests the current sample's depressive symptoms reflect their coping with ongoing stress of cancer diagnosis and treatment, rather than premorbid mental health issues. To assess whether severe depressive symptoms are related to disease outcomes, studies should consider inclusion of participants with severe levels of depressive symptoms and MDD [6] . Although our study was limited to the use of the HDRS, selfreported measures of depressive symptoms (Affect Balance Scale -depressive subscale and Center for Epidemiologic Studies Depression scale) were positively associated with the HDRS in our sample at baseline (r = 0.461, p b 0.001), and at 5-year follow-up (r = 0.313, p b 0.001), respectively. Generalizability is also limited by the academic study setting, geographical location of the study, and the fact that women were participating in an intervention trial. Although we controlled for major demographic and medical confounding variables, we did not have complete data on other factors (e.g., body mass index, medications, comorbidity index); therefore, these were not included in the model to maximize sample size, and to avoid overfitting the models [24] . Unfortunately, we do not have information on the mental or physical health status of women who did not participate in the study, therefore we cannot determine whether the current sample was more or less depressed than those choosing not to participate in a psychosocial study. Future research should examine longitudinal changes in depressive symptoms and the effect on survival [9] . Finally, studies should examine whether effective psychotherapeutic or pharmacological treatment of depressive symptoms during breast cancer treatment can decrease mortality [7] .
Conclusions
In summary, women with non-metastatic breast cancer who report mild to moderate depressive symptoms in the weeks after surgery have approximately 2.5 times greater risk of death 8-15 years later than women who report little or no depressive symptoms post-surgery. Depressive symptoms were not associated with breast cancer recurrence. Although the association between depression and all-cause mortality is well-established in the general population, our findings that depressive symptoms were associated with mortality in women with breast cancer are significant given that they are at higher risk for early mortality than the general population. Findings warrant a randomized trial to truly determine whether subclinical depressive symptoms may affect long-term clinical outcomes. 
